Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469199 | 0.88 | DPP4 (0.49) | DPP4ATML3MBTL1POLBVNN1 | |
| SCHEMBL6471110 | 0.87 | DPP4 (0.53) | DPP4PDPK1VNN1GRM2 | |
| SCHEMBL6471055 | 0.84 | MAOB (0.47) | DPP4MAOBAURKARPS6KB1AURKB | |
| SCHEMBL6468183 | 0.84 | POLB (0.40) | DPP4MAOBSMN1; SMN2CHEK1ATM | |
| SCHEMBL6470735 | 0.79 | VNN1 (0.43) | DPP4HDAC3HDAC1HDAC2VNN1 | |
| SCHEMBL5131614 | 0.79 | OPRK1 (0.53) | DPP4SMN1; SMN2ATML3MBTL1VNN1 | |
| SCHEMBL5133518 | 0.78 | DPP4 (0.44) | DPP4L3MBTL1VNN1 | |
| SCHEMBL6469026 | 0.78 | DPP4 (0.53) | DPP4ATML3MBTL1POLBVNN1 | |
| SCHEMBL5140232 | 0.78 | DPP4 (0.46) | DPP4MAOBSMN1; SMN2CHEK1ATM | |
| SCHEMBL5042774 | 0.78 | TMEM97 (0.57) | DPP4HDAC3HDAC1HDAC2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | claimed |
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | DPP4 3527/4885MAOB 50/4885SMN1; SMN2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.